273 related articles for article (PubMed ID: 6360536)
1. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans.
Reddy JK; Lalwai ND
Crit Rev Toxicol; 1983; 12(1):1-58. PubMed ID: 6360536
[TBL] [Abstract][Full Text] [Related]
2. [Proliferation of peroxisomes and the hepatocarcinogenic process].
Palut D
Rocz Panstw Zakl Hig; 1997; 48(1):1-11. PubMed ID: 9273657
[TBL] [Abstract][Full Text] [Related]
3. [Peroxisome proliferation and possible cancer hazard].
Dybing E; Sanner T
Tidsskr Nor Laegeforen; 1995 Jun; 115(15):1839-41. PubMed ID: 7638833
[TBL] [Abstract][Full Text] [Related]
4. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.
Lai DY
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2004 May; 22(1):37-55. PubMed ID: 15845221
[TBL] [Abstract][Full Text] [Related]
5. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk.
Huber WW; Grasl-Kraupp B; Schulte-Hermann R
Crit Rev Toxicol; 1996 Jun; 26(4):365-481. PubMed ID: 8817083
[TBL] [Abstract][Full Text] [Related]
6. Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643.
Rose ML; Germolec D; Arteel GE; Schoonhoven R; Thurman RG
Chem Res Toxicol; 1997 Oct; 10(10):1198-204. PubMed ID: 9348444
[TBL] [Abstract][Full Text] [Related]
7. Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease.
Youssef J; Badr M
Crit Rev Toxicol; 1998 Jan; 28(1):1-33. PubMed ID: 9493760
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver.
Lalwani ND; Reddy MK; Qureshi SA; Sirtori CR; Abiko Y; Reddy JK
Hum Toxicol; 1983 Jan; 2(1):27-48. PubMed ID: 6840792
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferators: a model for receptor mediated carcinogenesis.
Green S
Cancer Surv; 1992; 14():221-32. PubMed ID: 1330305
[TBL] [Abstract][Full Text] [Related]
10. [Peroxisomes and hypolipidemic agents ].
Heller F; Pourbaix S
Sem Hop; 1982 Jul; 58(28-29):1712-7. PubMed ID: 6289453
[TBL] [Abstract][Full Text] [Related]
11. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes.
Moody DE; Reddy JK
Am J Pathol; 1978 Feb; 90(2):435-46. PubMed ID: 623209
[TBL] [Abstract][Full Text] [Related]
12. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.
Ashby J; Brady A; Elcombe CR; Elliott BM; Ishmael J; Odum J; Tugwood JD; Kettle S; Purchase IF
Hum Exp Toxicol; 1994 Nov; 13 Suppl 2():S1-117. PubMed ID: 7857698
[TBL] [Abstract][Full Text] [Related]
13. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator.
Waxman DJ
J Endocrinol; 1996 Sep; 150 Suppl():S129-47. PubMed ID: 8943797
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
Rao MS; Lalwani ND; Watanabe TK; Reddy JK
Cancer Res; 1984 Mar; 44(3):1072-6. PubMed ID: 6692393
[TBL] [Abstract][Full Text] [Related]
15. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
16. Proliferation of myocardial peroxisomes caused by several agents and conditions.
Zipper J
J Mol Cell Cardiol; 1997 Jan; 29(1):149-61. PubMed ID: 9040030
[TBL] [Abstract][Full Text] [Related]
17. Differential induction and regulation of peroxisomal enzymes: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens.
Nemali MR; Reddy MK; Usuda N; Reddy PG; Comeau LD; Rao MS; Reddy JK
Toxicol Appl Pharmacol; 1989 Jan; 97(1):72-87. PubMed ID: 2916237
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferators: potential role of altered hepatocyte growth and differentiation in tumor development.
Cattley RC; Miller RT; Corton JC
Prog Clin Biol Res; 1995; 391():295-303. PubMed ID: 8532723
[TBL] [Abstract][Full Text] [Related]
19. Detection of peroxisome proliferators using a reporter construct derived from the rat acyl-CoA oxidase promoter in the rat liver cell line H-4-II-E.
Lee MJ; Gee P; Beard SE
Cancer Res; 1997 Apr; 57(8):1575-9. PubMed ID: 9108462
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals.
Lake BG
Annu Rev Pharmacol Toxicol; 1995; 35():483-507. PubMed ID: 7598504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
